Catharina Muylaert

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 25, 2024

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma.

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma.

Journal: British journal of pharmacology

Published: October 14, 2024

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Journal: Blood neoplasia

Published: June 24, 2024

Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma.

Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma.

Journal: Blood advances

Published: May 09, 2023

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.

Journal: Haematologica

Published: February 01, 2023

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.

Journal: Journal for immunotherapy of cancer

Published: December 30, 2022

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

Journal: Frontiers in oncology

Published: June 27, 2022

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.

Journal: Blood advances

Published: August 20, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026